NOMID/CINCA is a dubious disease in the field of autoimmune and rheumatic immunity, clinical performance is complex and often involves multi-system congestion. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
Treatment and management of neonatal multiple systemic inflammatory disease (NOMID/CINCA) needs to be individualized, typically including multidimensional management of drug therapy, rehabilitation interventions, regular follow-up, and more. In recent years, with the development of targeted therapy, immune-regulatory therapy, and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved. Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adjusting the regimen according to changes in the condition and timing.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of neonatal systemic inflammatory disease (NOMID/CINCA). The platform serves the China International Medical Service System, which combines national and international authorities in the field of autoimmunity and rheumatic immunity to provide the following services to patients: 1. Remote pre-diagnosis: pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2.
Interviews in China: arranging face-to-face diagnostics with authorities, developing personalized treatment plans; 3. Full-service: one-stop services: providing medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.
Support for remote pre-diagnosis, visiting interviews, full translation and escort.